Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Eric Ka‐Wai Hui"'
Autor:
Eric Ka-Wai Hui, 許家偉
87
Assembly of replication-competent hepatitis B virus (HBV) nucleocapsids requires the interaction of the virus encoded capsid core protein, polymerase, and encapsidation signal (e) of the viral pregenomic RNA (pgRNA). The wild type HBV core pr
Assembly of replication-competent hepatitis B virus (HBV) nucleocapsids requires the interaction of the virus encoded capsid core protein, polymerase, and encapsidation signal (e) of the viral pregenomic RNA (pgRNA). The wild type HBV core pr
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/37253515941813266061
Autor:
Tina Meng, Suzanne Bezstarosti, Ujjwala Singh, Michelle Yap, Laura Scott, Naiiry Petrosyan, Fred Quiroz, Ned Van Eps, Eric Ka‐Wai Hui, David Suh, Quansheng Zhu, Rui Pei, Cynthia S. M. Kramer, Frans H. J. Claas, David Lowe, Sebastiaan Heidt
Publikováno v:
HLA: Immune Response Genetics. WILEY
HLA: Immune Response Genetics
HLA: Immune Response Genetics
Eplet 44KM is currently listed in the HLA Epitope Registry but does not adhere to the eplet definition of an amino acid configuration within a 3.5 angstrom radius. Eplet 44KM has been previously redefined to the antibody-verified reactivity pattern 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76043def4403f4b09a9a3fdfebcc23cd
http://hdl.handle.net/1887/3570813
http://hdl.handle.net/1887/3570813
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
Scientific Reports
Scientific Reports
Most lysosomal storage disorders affect the central nervous system. However, lysosomal enzymes do not cross the blood-brain barrier (BBB), and intravenous enzyme infusion is not effective for the brain. Lysosomal enzymes can be re-engineered for BBB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43a8de8f860598c92da033df5d41efba
http://link.springer.com/article/10.1038/s41598-019-55136-4
http://link.springer.com/article/10.1038/s41598-019-55136-4
Publikováno v:
Molecular Pharmaceutics. 15:5207-5216
A monoclonal antibody (mAb) against the blood-brain barrier (BBB) transferrin receptor (TfR) is a potential agent for delivery of biologic drugs to the brain across the BBB. However, to date, no TfRMAb has been tested with chronic dosing in a primate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68403d2ee3f165e93f01586b3f29498f
https://doi.org/10.1021/acs.molpharmaceut.8b00730
https://doi.org/10.1021/acs.molpharmaceut.8b00730
Publikováno v:
Molecular Pharmaceutics. 13:3241-3246
Brain penetration of recombinant protein drugs is possible following the re-engineering of the drug as an IgG fusion protein. The IgG domain is a monoclonal antibody (mAb) against an endogenous blood-brain barrier (BBB) receptor transporter, such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efa5b89acff6e6920ff5cdf7bec3f733
https://doi.org/10.1021/acs.molpharmaceut.6b00456
https://doi.org/10.1021/acs.molpharmaceut.6b00456
Publikováno v:
Molecular Pharmaceutics. 13:1385-1392
Mucopolysaccharidosis Type IIIB (MPSIIIB) is caused by mutations in the gene encoding the lysosomal enzyme, α-N-acetylglucosaminidase (NAGLU). MPSIIIB presents with severe disease of the central nervous system, but intravenous NAGLU enzyme replaceme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::237eee312801af9e75c8a6085f89b6ab
https://doi.org/10.1021/acs.molpharmaceut.6b00037
https://doi.org/10.1021/acs.molpharmaceut.6b00037
Publikováno v:
Molecular Genetics and Metabolism. 126:S114-S115
Batten disease has primary brain manifestations. Progress in the treatment has primarily been limited to the fact that recombinant enzymes are large molecules that do not cross the blood-brain barrier (BBB). BBB-penetration of enzyme therapeutics is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98895d4f57005b3c0fa45af281d1349f
https://doi.org/10.1016/j.ymgme.2018.12.291
https://doi.org/10.1016/j.ymgme.2018.12.291
Publikováno v:
Molecular Genetics and Metabolism. 126:S95-S96
The majority of lysosomal storage disorders (LSD) affect the brain. Intravenous enzyme replacement therapy does not treat the brain, because recombinant enzymes are large molecules that do not cross the blood-brain barrier (BBB). BBB-penetration of e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69226b2535e09a4c7a5689ddf04334a6
https://doi.org/10.1016/j.ymgme.2018.12.238
https://doi.org/10.1016/j.ymgme.2018.12.238
Publikováno v:
Molecular pharmaceutics. 15(2)
Mucopolysaccharidosis Type IIIA (MPSIIIA), also known as Sanfilippo A syndrome, is an inherited neurodegenerative disease caused by mutations in the lysosomal enzyme, N-sulfoglucosamine sulfohydrolase (SGSH), also known as sulfamidase. Mutations in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27278ea16d473829fdd2599cc6cbc2bf
https://pubmed.ncbi.nlm.nih.gov/29251941
https://pubmed.ncbi.nlm.nih.gov/29251941
Publikováno v:
Biotechnology and Bioengineering. 111:2317-2325
Mucopolysaccharidosis (MPS) Type II is caused by mutations in the gene encoding the lysosomal enzyme, iduronate 2-sulfatase (IDS). The majority of MPSII cases affect the brain. However, enzyme replacement therapy with recombinant IDS does not treat t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d3479ee6061670f6436089ff8f46219
https://doi.org/10.1002/bit.25289
https://doi.org/10.1002/bit.25289